IQVIA Holdings Inc. $IQV Shares Purchased by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,463 shares of the medical research company’s stock after buying an additional 5,271 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in IQVIA were worth $3,697,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Verdence Capital Advisors LLC purchased a new stake in IQVIA in the 2nd quarter worth approximately $3,612,000. Amundi boosted its holdings in IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after purchasing an additional 405,250 shares in the last quarter. Act Two Investors LLC bought a new position in IQVIA during the second quarter valued at about $26,528,000. Diversified Trust Co lifted its position in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares during the last quarter. Finally, Patton Fund Management Inc. bought a new stake in shares of IQVIA during the 2nd quarter worth about $231,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $242.70 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $41.33 billion, a PE ratio of 33.29, a price-to-earnings-growth ratio of 2.47 and a beta of 1.36. The firm has a fifty day moving average price of $224.37 and a two-hundred day moving average price of $200.77. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.05.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IQV. UBS Group raised their price objective on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday. Barclays set a $230.00 price target on shares of IQVIA in a research report on Monday, December 15th. Mizuho set a $266.00 price objective on shares of IQVIA in a report on Friday. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Finally, Stifel Nicolaus raised their price target on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.